J&J/Janssen schizophrenia drug Invega Trinza OK'd
This article was originally published in Scrip
Executive Summary
Johnson & Johnson unit Janssen on 19 May won approval from the FDA to market Invega Trinza (three-month paliperidone palmitate), an atypical antipsychotic, to treat schizophrenia – the first and only medication administered just four times a year, providing the longest dosing interval available.